An overview of reform initiatives relating to low risk therapeutic goods and the scheduling policy framework arising from the Review of Medicines and Medical Devices Regulation.
Presentation: Conformity assessment evidenceTGA Australia
An overview of Conformity Assessment requirements and General Safety and Performance Requirements and demonstrating compliance in the Australian context.
Presentation: Pharmacovigilance: The Australian landscapeTGA Australia
Overview of current post-market monitoring regulations and practice in Australia. Focusing on changing trends and the implications for future post-market vigilance practice.
Presentation: Spotlight on prescription medicines reformsTGA Australia
An overview of initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines as well as orphan drugs and developments for eCTD and the new MedSearch app.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
Presentation: Conformity assessment evidenceTGA Australia
An overview of Conformity Assessment requirements and General Safety and Performance Requirements and demonstrating compliance in the Australian context.
Presentation: Pharmacovigilance: The Australian landscapeTGA Australia
Overview of current post-market monitoring regulations and practice in Australia. Focusing on changing trends and the implications for future post-market vigilance practice.
Presentation: Spotlight on prescription medicines reformsTGA Australia
An overview of initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines as well as orphan drugs and developments for eCTD and the new MedSearch app.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
Expert review of medicines and medical devices regulation: Prescription medic...TGA Australia
This presentation outlines proposals for implementation of several recommendations from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, and the use of overseas assessment reports.
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
An overview of reform initiatives relevant to prescription medicines pharmacovigilance arising from the Review of Medicines and Medical Devices Regulation.
Online Clinical Trial Notification (CTN)TGA Australia
This presentation provides a brief background on the TGA's role in the regulation of clinical trials as well as guidance on using the new online Clinical Trial Notification form
Presentation: Updates from the Therapeutic Goods Administration - For medicin...TGA Australia
The presentation outlines how the TGA’s new priority review pathway for prescription medicines works and how medicines might be deemed to be a priority for Australian patients. We discuss how the provisional approval pathway contributes to early access and how to judge when early data seems promising.
This presentation provides an overview of proposals for implementation of several reform initiatives relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, the use of overseas assessment reports, and reforms to the orphan drug programs. The information session was held ahead of formal public consultations to provide an early view of the reform proposals to those stakeholders who will be most directly involved in the design of the new regulatory arrangements.
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Expert review of medicines and medical devices regulation: Prescription medic...TGA Australia
This presentation outlines proposals for implementation of several recommendations from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, and the use of overseas assessment reports.
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
An overview of reform initiatives relevant to prescription medicines pharmacovigilance arising from the Review of Medicines and Medical Devices Regulation.
Online Clinical Trial Notification (CTN)TGA Australia
This presentation provides a brief background on the TGA's role in the regulation of clinical trials as well as guidance on using the new online Clinical Trial Notification form
Presentation: Updates from the Therapeutic Goods Administration - For medicin...TGA Australia
The presentation outlines how the TGA’s new priority review pathway for prescription medicines works and how medicines might be deemed to be a priority for Australian patients. We discuss how the provisional approval pathway contributes to early access and how to judge when early data seems promising.
This presentation provides an overview of proposals for implementation of several reform initiatives relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, the use of overseas assessment reports, and reforms to the orphan drug programs. The information session was held ahead of formal public consultations to provide an early view of the reform proposals to those stakeholders who will be most directly involved in the design of the new regulatory arrangements.
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Complementary medicines MMDR reforms: Assessment pathwaysTGA Australia
An overview of the reform initiatives relevant to complementary medicines. Topics include the implementation of recommendations from the Review of Medicines and Medical Devices Regulation.
Regulatory affairs in Pharmaceutical IndustryRama Shukla
Regulatory affairs is a profession developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines.
Pharmacovigilance - a regulator's perspectiveTGA Australia
This presentation provides an overview of the TGA's Pre-market and Post-market pharmacovigilance methods. It describes the role and content of Risk Management Plans as well as adverse event reporting and signal detection and investigation.
Overview of the Complementary Medicines regulatory frameworkTGA Australia
This presentation provides an overview traditional Chinese Medicines with the complementary medicines regulatory framework and the future of complementary medicine regulation
The Therapeutic Goods Administration or TGA is the regulatory body for therapeutic goods in Australia.
The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard.
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
The world of Regulatory convergence: an Australian reflectionTGA Australia
This presentation provides an overview on recent advances and initiatives on regulatory convergence and the impact on Australian, European and international regulation of therapeutic goods.
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation.
Similar to Spotlight on MMDR Further Reviews and Advertising Reforms (20)
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Spotlight on MMDR Further Reviews and Advertising Reforms
1. Regulatory Reforms at the Therapeutic
Goods Administration (TGA)
Dr Mark McDonald
Assistant Secretary
Regulatory Reforms, TGA
2017 ARCS Annual Conference
2. Risk management
• All therapeutic goods have some level of risk
• Our role is to see that benefits outweigh known risks.
Management of uncertainty is a greater challenge
TGA’s approach to risk management involves:
• identifying, assessing and evaluating the risks posed by
therapeutic products
• applying any measures necessary for treating the risks
posed
• monitoring and reviewing risks over time
Regulatory Reforms at the Therapeutic Goods Administration
1
3. Can regulators manage uncertainty well
enough?
• Regulators have frameworks for assessing benefits and harms (risk) but
less with uncertainty
• Uncertainty and harms can be confused, with negative consequences
for decision making
• A balance between the two is needed, combining the science with an
appropriately designed regulatory framework
Regulatory Reforms at the Therapeutic Goods Administration 2
4. Review of Medicines & Medical Devices Regulation
• Expert Panel commenced late 2014 after most of 2014 in pre-work
• Review process included discussion papers, submissions and interviews by the panel
• Two reports on medicines and devices and complementary medicines and advertising
released during 2015 with 58 recommendations
• Following release of the reports, workshops held with key stakeholders by the Department
to get feedback on recommendations
• Health Minister took preferred position to Cabinet
• Government response was publicly released on 15 September 2016
Regulatory Reforms at the Therapeutic Goods Administration 3
5. Key principles endorsed by Government
• The Australian Government retain responsibility for approval of
therapeutic goods rather than automatically accepting international approvals,
but TGA needs to:
− make greater use of overseas evaluations
− introduce greater flexibility in approval pathways for both medicines and
medical devices
− more appropriately align level regulation with the actual risk posed
by certain types of products
Regulatory Reforms at the Therapeutic Goods Administration 4
6. Further reviews to be undertaken
In scope
• Medicines (and chemicals) Scheduling Policy Framework
• Schedule 3 medicine advertising guidelines
• Review regulation of lower-risk medicines
Proposed process
• Document the basis of current approaches, approach of
other regulators, and alternative frameworks
• Conduct stakeholder workshops
• Consultation papers and formal feedback on options
• Provide advice to Minister on options
• Ministerial decision, change to regulations?
Regulatory Reforms at the Therapeutic Goods Administration 5
7. To Regulate or Not to Regulate
• TGA regulatory frameworks
– Exempt goods
– Excluded goods
• Consumer goods (ACCC)
Regulatory Reforms at the Therapeutic Goods Administration 6
8. Guiding principles of the review
• Not our intention to fundamentally change the definition of a medicine or medical device.
• What is the purpose of our regulation
• Considered the concept of ‘regulatory familiarity’ of particular products
• Recognised that moving some product types to regulation by Food Standards Australian
New Zealand (FSANZ) or under the National Industrial Chemicals Notification and
Assessment Scheme (NICNAS) are not necessarily options that provide for decreasing
regulation
• Australian Consumer Law provides for default Australian Competition and Consumer
Commission (ACCC) oversight of all consumer goods in Australia under Australian
Consumer Law, including therapeutic goods used by consumers
Regulatory Reforms at the Therapeutic Goods Administration 7
9. Next steps: Identify product types in scope
• Water-soluble vitamins and minerals, homeopathic
products?
• Medicated lozenges
• Primary and secondary sunscreens
• Disinfectants, medicated soaps and toothpastes,
nappy rash treatments
• Some class one medical devices
• Sanitary tampons
• Other products?
Regulatory Reforms at the Therapeutic Goods Administration 8
10. Next steps: Develop a risk framework
• How to define “low risk”?
• For medicinal products, this could include parameters such as:
– safety of the ingredients
– route of administration
– risk associated with the claims including labelled use
– nature of the condition being treated/ prevented
– nature and number of the population using the product
– impact of poor manufacturing quality on safety/ efficacy
• Regulatory ‘familiarity’ - does this reduce uncertainty or actual risks?
• What is the ability of sponsors to objectively self-assess the product ?
• Look at international experience/alternative regulatory approaches
Regulatory Reforms at the Therapeutic Goods Administration 9
11. Low Risk Classification System
• To objectively determine if products are ‘low risk’ the TGA developed a Low Risk
Classification System (LRCS) in consultation with experts in this area from the University
of Melbourne
• The basic principle of the LCRS
• This approach is increasing used to publicly rate hotels and restaurants
(e.g. on “Trip Advisor”), car smash repairers and even health care providers
“Wisdom of crowds” Linear model
Rate
Experts
qualitatively rate
a product on
each of six
criteria
Combine
Take average of
ratings on each
criterion
Weight
Multiply
averaged ratings
by criteria
weights
Sum
Calculate a
product’s Score
as sum of
weighted ratings
Classify
Low Risk if
Score Less than
Threshold
Regulatory Reforms at the Therapeutic Goods Administration 10
12. So what was considered ‘low risk’
In the context of Recommendation 14 of this review the following was considered ‘low risk’:
• Ear candles
• Nappy rash creams
• Antiperspirants
• ‘Low risk’ OTC medicines
• Hard surface disinfectants
• Sunscreens
• Tampons and menstrual cups
TGA developed a range of possible options that represent potential future regulatory
approaches.
Regulatory Reforms at the Therapeutic Goods Administration 11
13. ‘Low risk’ OTC medicines
A number of well-known OTC products that have a long history of use at particular
ingredient levels and dosage forms have been identified as ‘lower risk’.
These product types include:
• Registered desensitising toothpastes
• Antiseptics for first aid treatment of minor cuts and abrasions
• Lozenges for relief of sore throats
(these contain anti-microbial active ingredients)
• Antacids – containing carbonates, hydroxides, silicates, and/or alginates
(but not medicines containing a proton pump inhibitor or H2 antagonist)
• Salicylic acid plasters for removal of corns and warts
• Menthol-based inhalers and chest rubs
Regulatory Reforms at the Therapeutic Goods Administration 12
14. ‘Low risk’ OTC medicines
Product types continued:
• Antiseptic mouth washes
• Acne treatments containing benzoyl peroxide
• Rubefacient preparations for minor aches and pains of muscles (e.g. methyl salicylate,
menthol, capsicum) but not creams or ointments containing a non-steroidal anti-
inflammatory medicine
• Certain laxatives
Options
• Maintain the status quo regulation
• Review the eligibility of active ingredients to become Listable
Regulatory Reforms at the Therapeutic Goods Administration 13
15. Hard surface disinfectants
Issues identified by stakeholders with the current framework include:
• Regulatory requirements are confusing
• Timeframes for application processing are very long
• Safety evaluations for different formulations are expensive
Range of options:
• Maintain the status quo regulation of hard surface disinfectants
• Streamline the regulatory framework for hard surface disinfectants
• Develop a series of monographs
• Approval process for new ingredients
• Declare hard surface disinfectants not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 14
16. Sunscreens
Issues identified by stakeholders with the current
framework include:
• Medicine level GMP
• Process for review of new ingredients slow
and expensive
• Application of pharmacopeial standards for
all ingredients
• Different levels of regulation confusing
Range of options:
• Maintain the status quo regulation of sunscreens
• Streamline the regulatory pathways for sunscreen
regulation
• Prevent all secondary sunscreens from making
SPF claims
• Creation of a GMP standard for primary
sunscreens
• New ingredient approval process
• Alternative ingredient standards for excipients
• Exclude all sunscreens from the regulatory
framework
Regulatory Reforms at the Therapeutic Goods Administration 15
17. So what was considered ‘low risk’
Recommendation 23 was the review of Class I medical devices.
• To maintain international harmonisation we did not want to fundamentally change the
classification system for medical devices
• Whilst trying to identify candidates for consideration it was recognised that there is a
significant number of potentially non therapeutic goods in the ARTG
• Proposal is to clean up the ARTG to remove the ‘white noise’ before taking a look at
those remaining Class I medical devices, and consider any further regulatory changes
Regulatory Reforms at the Therapeutic Goods Administration 16
18. So what was considered ‘low risk’
In the context of Recommendation 48 of this review the following was considered ‘low risk’:
• Aromatherapy products
• Rehydration or formulated sports products
• Certain vitamins and minerals
• Homoeopathic products
Again, TGA developed a range of possible options that represent
future regulatory approaches.
Regulatory Reforms at the Therapeutic Goods Administration 17
19. Aromatherapy products
Aromatherapy uses essential oils for the purpose of altering one's mood, cognitive,
psychological or physical wellbeing.
Issues with the current approach include:
• the purpose of a product containing an essential oil determines which part of government
regulates it
• The difference between therapeutic and cosmetic products can be confusing
Range of options:
• Maintain the status quo regulation of aromatherapy products
• Exemption from listing in the ARTG and/or GMP
• Declare essential oils not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 18
20. Rehydration or formulated sports products
Issue with the current approach include:
• confusion at the food-medicine interface
• the dosage forms for these products range from sachets of oral powders and
effervescent tablets to ice blocks and ready to drink solutions
• rehydration products are similar in composition and presentation to electrolyte drinks,
also known as sports drinks, which are beverages designed specifically for the rapid
replacement of fluid, carbohydrates, and electrolytes
Proposed further action:
• Review of rehydration products on the ARTG to remove food claims to ensure clear
demarcation between sports drinks and therapeutic rehydration products
Regulatory Reforms at the Therapeutic Goods Administration 19
21. Certain vitamins and minerals
Not all of these supplements represent equal risk
• Water soluble vitamins (for example vitamin C) have a lower
risk profile than fat soluble vitamins (for example vitamin A)
as they are readily excreted from the body, whereas fat
soluble vitamins have been associated with toxicity
• Similarly minerals such as calcium have a lower risk profile,
compared to higher risk minerals which are included in a
schedule of the Poisons Standard, such as some iron
preparations
Regulatory Reforms at the Therapeutic Goods Administration 20
22. Certain vitamins and minerals
Issues with the current approach include:
• the introduction of Standard 1.2.7 – Nutrition, Health and Related Claims in 2013 by
Food Standards Australia New Zealand (FSANZ) has caused a significant change to the
food/medicine interface
• Some vitamin and mineral products are more akin to food or dietary supplements than
medicines
Range of options:
• Maintain the status quo regulation of vitamins and minerals
• Exemption from listing in the ARTG and/or GMP
• Declare certain vitamins and minerals not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 21
23. Homoeopathic products
• Homoeopathic preparations (4X and above) are exempt from
being entered in the ARTG if they:
– are not required to be sterile
– do not include ingredients of human or animal origin, and
– do not make reference to serious diseases or conditions.
• Preparations that meet these conditions are also exempt from
requiring the manufacturer to hold a GMP licence
Regulatory Reforms at the Therapeutic Goods Administration 22
24. Homoeopathic products
Issues identified with the current approach include:
• Questionable evidence
• Inconsistency in regulation for level of claims being made, ie homoeopathic products
making high level claims must be listed. Other non homoeopathic products making high
level claims are required to be registered
Range of options:
• Maintain the status quo regulation of homoeopathic products
• Serious therapeutic claims must be supported by scientific evidence
• Exemption from listing in the ARTG and/or GMP
• Declare homeopathic products not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 23
25. Where are we up to?
• Public consultation on the “Options for the future regulation of ‘low risk’
products” has been completed and analysed
• Specific policy proposals are being developed for Ministerial consideration
• Following Ministerial endorsement of proposals, implementation proposals will
be developed and consulted
Regulatory Reforms at the Therapeutic Goods Administration 24
26. Class I medical devices
Proposed next steps:
• Systematic review of ARTG to identify non therapeutic goods
• Engage with States and Territories Health department procurement branches
• Update the Excluded Goods Order
• Review the Class I medical device ARTG entry process
Regulatory Reforms at the Therapeutic Goods Administration 25
27. The Scheduling Policy Framework - background
• The SUSMP is the basis by which public access to medicines and chemicals is controlled
• Substances are placed into a schedule based on the risk associated with their use
• Progression through the schedules signifies increasing restrictions
• For medicines: S2, S3, S4 and S8
• For chemicals: S5, S6 and S7
• S9: only available for teaching, research etc
• Decision making powers contained in the Therapeutic Goods Act 1989, i.e. delegates of
the Secretary of the Department of Health make the actual scheduling decisions
• The SPF provides the risk based decision making principles to be used by the decision
maker – the scheduling decision is captured by the SUSMP
• Implementation of the SUSMP is through relevant State and Territory legislation
Regulatory Reforms at the Therapeutic Goods Administration 26
28. SPF - considerations for reform
Policy recommendations
Governance 1 Split the SPF into a policy document and a guidance handbook.
2
Establish an informal working group comprising state and territory representatives,
industry, healthcare professionals and consumers to meet as required to provide advice
on possible amendments to the SUSMP
Interim decision 3
Amend the Therapeutic Goods Regulations to allow general public consultation on the
interim decision and where appropriate, enable the time available for submissions to be
extended.
Timing of
decision
4
Explore options for establishing a chemicals scheduling delegate in APVMA to streamline
scheduling and marketing authorisation considerations.
Tools for better
management of
rescheduled
substances
5
Create a new Appendix in the Poisons Standard (SUSMP) to enable additional controls or
requirements for Schedule 3 substances to be specified, in particular for substances that
have been down-scheduled from Schedule 4 (prescription only).
Regulatory Reforms at the Therapeutic Goods Administration
27
29. SPF - considerations for reform
Ongoing improvements and development of guidance materials
Decision-making
principles
1
Undertake a trial to assess the value of applicants presenting to the advisory
committees
Risk-benefit value tree 2
Prepare worked examples of the risk-benefit tree for recent scheduling
considerations and determine if there is utility for using as part of scheduling
applications
Proactive consideration
of candidate substances
for rescheduling
3 Implement a system for proactively identifying substances for rescheduling
Parallel processes 4A
Develop a possible mechanism for aligning prescription to OTC medicine
rescheduling applications with applications to TGA for market authorisation of
products containing the potentially rescheduled substances at OTC medicines
4B Consider options for market incentives for down-scheduling
Further process
improvements
5 To improve, clarity and communication
Regulatory Reforms at the Therapeutic Goods Administration 28
30. S3 (pharmacist only) medicines advertising
• Currently only a limited number of S3 medicines can be advertised – managed through an
appendix to the SUSMP
• The Expert Panel found very diverse views on possible change
• Government has asked for more specific consultation to be conducted
• 2017 consultation asked stakeholders for their feedback on possible options in order to develop a
new framework for the advertising of these substances. Options included:
– Make no change to the current system
– Move instead to having a small list of substances forbidden from advertising
– Move to a self-regulatory approach
– Allow “information provision” by industry but not advertising
• There was strong support to increase advertising of Schedule 3 substances, with a particular
emphasis on public health awareness. Current work is focused on developing a mechanism, utilising
existing framework to allow more S3 substances to be advertised
Regulatory Reforms at the Therapeutic Goods Administration 29
31. Timeline for Scheduling Review
Advertising Reform (including S3)
consultation September 2017
Revised advertising code
(including S3) to be consulted
Mid 2018 implemented
SPF policy and handbook being drafted
Public/Targeted consultation
AHMAC consideration of revised
SPF/handbook
December 2017
Implementation to commence
Start of 2018
Regulation change
(if required as part of bulk legislative change)
Regulatory Reforms at the Therapeutic Goods Administration
30